Form 4: Luke Evnin Reports Werewolf Therapeutics Stock Transactions

Luke Evnin, a Director at Werewolf Therapeutics, Inc., reported transactions involving the sale of common stock under a Rule 10b5-1 trading plan.

Summary

• Luke Evnin, a Director of Werewolf Therapeutics, Inc. (HOWL), has reported a sale of common stock.
• The transaction occurred on June 29, 2026, and was executed under a pre-established Rule 10b5-1 trading plan dated March 26, 2026.
• A total of 157,084 shares of common stock were sold at a weighted average price of $0.30 per share, with individual sale prices ranging from $0.2703 to $0.33.
• These shares were held by various entities associated with MPM, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BIoVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.
• Following these transactions, Luke Evnin directly beneficially owns 143,199 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a director, despite being executed under a pre-planned 10b5-1 strategy.

Negatives

• Sale of a significant number of shares (157,084) by a Director.
• The sale occurred at a relatively low price point, with a weighted average of $0.30 per share.

Risks

• The sale of shares by a company insider, even under a 10b5-1 plan, can sometimes be interpreted negatively by the market.
• The weighted average sale price indicates a range of prices, suggesting potential downward pressure or a need to liquidate at various market levels.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for managing personal finances and diversifying holdings. However, the volume and price point of this sale by a Director warrant attention within the biotechnology sector, where stock performance can be volatile.

Stakeholder Impact

• Shareholders may view the sale of a large number of shares by a director as a potential negative signal, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The sale does not appear to directly impact employees, customers, suppliers, or creditors based on the information provided.

Key Dates

Recommendation

The filing reports a sale of stock by a director under a Rule 10b5-1 plan. While insider selling can be a negative indicator, the pre-planned nature of the transaction suggests it may be for personal financial management rather than a reflection of negative company outlook. Without additional financial performance data or strategic updates, a 'hold' recommendation is prudent, advising investors to monitor future filings and company performance.

Keywords

Werewolf Therapeutics, HOWL, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Luke Evnin, Director, Common Stock, Beneficial Ownership